Ocular Therapeutix (NASDAQ:OCUL) Share Price Passes Above 50 Day Moving Average of $5.66

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.66 and traded as high as $6.70. Ocular Therapeutix shares last traded at $6.51, with a volume of 882,673 shares.

Analysts Set New Price Targets

OCUL has been the subject of a number of research analyst reports. JMP Securities lifted their price target on shares of Ocular Therapeutix from $11.00 to $12.00 in a research note on Tuesday, May 9th. Robert W. Baird started coverage on shares of Ocular Therapeutix in a research note on Thursday, April 20th. They issued an “outperform” rating and a $18.00 price target for the company. StockNews.com downgraded shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Finally, HC Wainwright dropped their price objective on shares of Ocular Therapeutix from $11.00 to $10.00 in a report on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average target price of $12.80.

Ocular Therapeutix Price Performance

The firm’s 50-day moving average is $5.66 and its two-hundred day moving average is $4.51. The company has a market cap of $504.72 million, a P/E ratio of -5.47 and a beta of 1.31. The company has a debt-to-equity ratio of 5.63, a current ratio of 3.61 and a quick ratio of 3.53.

Ocular Therapeutix (NASDAQ:OCUL – Get Rating) last posted its quarterly earnings data on Monday, March 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. Ocular Therapeutix had a negative net margin of 171.85% and a negative return on equity of 213.57%. The business had revenue of $14.08 million for the quarter, compared to analysts’ expectations of $13.60 million. Analysts anticipate that Ocular Therapeutix, Inc. will post -1.18 earnings per share for the current year.

Institutional Trading of Ocular Therapeutix

A number of large investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its stake in shares of Ocular Therapeutix by 0.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 206,249 shares of the biopharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 1,720 shares during the period. FMR LLC boosted its stake in shares of Ocular Therapeutix by 84.4% during the first quarter. FMR LLC now owns 4,751 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 2,175 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of Ocular Therapeutix by 61.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 9,225 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 3,500 shares during the period. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Ocular Therapeutix by 13.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 34,873 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 4,045 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Ocular Therapeutix by 22.2% during the fourth quarter. Principal Financial Group Inc. now owns 24,566 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 4,471 shares during the period. 55.40% of the stock is owned by hedge funds and other institutional investors.

About Ocular Therapeutix

(Get Rating)

Ocular Therapeutix, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.